Lowest-Rated StocksLowest-RatedNASDAQ:YMAB Y-mAbs Therapeutics (YMAB) Stock Price, News & Analysis $8.61 0.00 (0.00%) As of 09/16/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Y-mAbs Therapeutics Stock (NASDAQ:YMAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Y-mAbs Therapeutics alerts:Sign Up Key Stats Today's Range$8.61▼$8.6150-Day Range$4.19▼$8.6152-Week Range$3.55▼$16.11VolumeN/AAverage Volume676,583 shsMarket Capitalization$391.24 millionP/E RatioN/ADividend YieldN/APrice Target$9.62Consensus RatingReduce Company Overview Y-mAbs Therapeutics is a clinical‐stage biopharmaceutical company focused on developing antibody-based cancer immunotherapies for pediatric and adult patients. Leveraging proprietary antibody engineering and radiolabeling platforms, the company targets solid tumors and central nervous system malignancies that express the GD2 antigen. Its research approach combines monoclonal antibodies with radioconjugates to selectively deliver therapeutic payloads to cancer cells. The company’s lead product, DANYELZA (naxitamab-gqgk), received U.S. Food and Drug Administration approval in 2020 for the treatment of high-risk neuroblastoma in pediatric and young adult patients whose disease has not progressed after multi-cycle chemotherapy. In addition to its marketed therapy, Y-mAbs is advancing omburtamab, a radiolabeled monoclonal antibody designed to target metastatic or leptomeningeal tumors in the central nervous system. The pipeline also includes earlier-stage antibody candidates exploring novel targets in solid tumors. Headquartered in New York, Y-mAbs is domiciled in Switzerland and conducts clinical trials across North America, Europe and Australia. Commercial operations for DANYELZA extend into the United States and Canada, with expanded access programs facilitating treatment for patients outside traditional trial settings. Through collaborations with leading research institutions, the company continues to broaden its development footprint in pediatric oncology. Founded in 2016 out of collaborative research efforts, Y-mAbs operates under a management team with extensive experience in oncology drug development and regulatory strategy. The company’s scientific leadership and board comprise veterans of both large-cap pharmaceutical firms and specialized biotech startups, supporting its mission to bring targeted immunotherapies to underserved cancer populations.AI Generated. May Contain Errors. Read More Y-mAbs Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreYMAB MarketRank™: Y-mAbs Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 714th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.8 / 5Analyst RatingReduce Consensus RatingY-mAbs Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no buy ratings, 8 hold ratings, and 2 sell ratings.Upside PotentialY-mAbs Therapeutics has a consensus price target of $9.62, representing about 11.8% upside from its current price of $8.61.Amount of Analyst CoverageY-mAbs Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Y-mAbs Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Y-mAbs Therapeutics are expected to grow in the coming year, from ($0.65) to ($0.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Y-mAbs Therapeutics is -17.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Y-mAbs Therapeutics is -17.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioY-mAbs Therapeutics has a P/B Ratio of 4.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Y-mAbs Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.36% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldY-mAbs Therapeutics does not currently pay a dividend.Dividend GrowthY-mAbs Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.36% of the float of Y-mAbs Therapeutics has been sold short.Short Interest Ratio / Days to CoverY-mAbs Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Y-mAbs Therapeutics has recently increased by 11.45%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.97 News SentimentY-mAbs Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Y-mAbs Therapeutics this week, compared to 4 articles on an average week.MarketBeat FollowsOnly 2 people have added Y-mAbs Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Y-mAbs Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders19.70% of the stock of Y-mAbs Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions70.85% of the stock of Y-mAbs Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Y-mAbs Therapeutics' insider trading history. Receive YMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. YMAB Stock News HeadlinesY-Mabs Therapeutics Completes Merger with Perseus BidCoSeptember 16 at 9:30 AM | tipranks.comY-Mabs Therapeutics’ Phase 2 Trial: A Potential Breakthrough for Neuroblastoma TreatmentSeptember 7, 2025 | msn.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.September 18 at 2:00 AM | Paradigm Press (Ad)Y-MABS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMABAugust 19, 2025 | globenewswire.comAcquisition Deal Triggers Weekly Surge for Y-mAbs Therapeutics StockAugust 13, 2025 | insidermonkey.comA Look Ahead: Y-mAbs Therapeutics's Earnings ForecastAugust 9, 2025 | benzinga.comShareholder Alert: The Ademi Firm Investigates Whether Y-mAbs Therapeutics Inc. is Obtaining a Fair Price for its Public ShareholdersAugust 8, 2025 | businesswire.comY-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate DevelopmentsAugust 8, 2025 | globenewswire.comSee More Headlines YMAB Stock Analysis - Frequently Asked Questions How have YMAB shares performed this year? Y-mAbs Therapeutics' stock was trading at $7.83 at the beginning of 2025. Since then, YMAB stock has increased by 10.0% and is now trading at $8.61. How were Y-mAbs Therapeutics' earnings last quarter? Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) announced its quarterly earnings results on Friday, August, 8th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.20. The business had revenue of $19.52 million for the quarter, compared to analysts' expectations of $18.40 million. Y-mAbs Therapeutics had a negative net margin of 26.03% and a negative trailing twelve-month return on equity of 24.60%. When did Y-mAbs Therapeutics IPO? Y-mAbs Therapeutics (YMAB) raised $80 million in an initial public offering (IPO) on Friday, September 21st 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Canaccord Genuity acted as the underwriters for the IPO and BTIG was co-manager. Who are Y-mAbs Therapeutics' major shareholders? Y-mAbs Therapeutics' top institutional shareholders include Acorn Capital Advisors LLC (7.52%), Nantahala Capital Management LLC (0.77%), Stonepine Capital Management LLC (0.63%) and Bank of America Corp DE (0.60%). Insiders that own company stock include Biotech Aps Wg, Johan Wedell-Wedellsborg, Bo Kruse, Thomas Gad, Michael J Rossi, Vignesh Rajah and Joris Wilms. View institutional ownership trends. How do I buy shares of Y-mAbs Therapeutics? Shares of YMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Y-mAbs Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Y-mAbs Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL). Company Calendar Last Earnings8/08/2025Today9/18/2025Next Earnings (Estimated)11/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:YMAB CIK1722964 Webwww.ymabs.com Phone(646) 885-8505FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Price Target for Y-mAbs Therapeutics$9.62 High Price Target$17.00 Low Price Target$3.00 Potential Upside/Downside+11.8%Consensus RatingReduce Rating Score (0-4)1.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.67 million Net Margins-26.03% Pretax Margin-26.49% Return on Equity-24.60% Return on Assets-18.89% Debt Debt-to-Equity RatioN/A Current Ratio4.00 Quick Ratio3.58 Sales & Book Value Annual Sales$87.68 million Price / Sales4.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.05 per share Price / Book4.20Miscellaneous Outstanding Shares45,440,000Free Float36,487,000Market Cap$391.24 million OptionableOptionable Beta0.54 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:YMAB) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.